| 1 |
Tian C， Li L， Liu T， et al.Circulating antibodies against M-type phospholipase A2 receptor and thrombospondin type-1 domain-containing 7A in Chinese patients with membranous nephropathy［J］.Int Urol Nephrol， 2019， 51 (8): 1371-1377.
|
| 2 |
Zhang D， Zou J， Zhang C， et al.Clinical and histological features of phospholipase A2 receptorassociated and thrombospondin type-I domain-containing 7A-associated idiopathic membranous nephropathy: a single center retrospective study from China ［J］.Med Sci Monit， 2018 (24): 5076-5083.
|
| 3 |
Kollner SMS， Seifert L， Zahner G， et al.Strategies towards antigen-specific treatments for membranous nephropathy［J］.Front Immunol， 2022 (13): 822508.
|
| 4 |
Ou JY， Chen YW， Li TL， et al.Evaluation of efficacy of rituximab for membranous nephropathy: a systematic review and meta-analysis of 11 studies［J］.Nephrol Ther， 2022， 18 (2): 104-112.
|
| 5 |
Rovin BH， Adler SG， Barratt J， et al.Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases ［J］.Kidney Int，2021， 100 (4): 753-779.
|
| 6 |
Fervenza FC， Appel GB， Barbour SJ， et al.Rituximab or cyclosporine in the treatment of membranous nephropathy［J］.N Engl J Med， 2019， 381 (1): 36-46.
|
| 7 |
Scolari F， Delbarba E， Santoro D， et al.Rituximab or cyclophosphamide in the treatment of membranous nephropathy: the RI-CYCLO randomized trial［J］.J Am Soc Nephrol， 2021， 32 (4): 972-982.
|
| 8 |
Hu X， Zhang M， Xu J， et al.Comparison of obinutuzumab and rituximab for treating primary membranous nephropathy ［J/OL］.Clin J Am Soc Nephrol， 2024.https://journals.lww.com/cjasn/abstract/9900/comparison_of_obinutuzumab_and_rituximab_for.451.aspx.［published online ahead of print Aug 29， 2024］.
|
| 9 |
Sethi S， Kumar S， Lim K， et al.Obinutuzumab is effective for the treatment of refractory membranous nephropathy ［J］.Kidney Int Rep， 2020， 5 (9): 1515-1518.
|
| 10 |
Lin Y， Han Q， Chen L， et al.Obinutuzumab in refractory membranous nephropathy: a case series［J］.Kidney Med， 2024， 6 (8): 100853.
|
| 11 |
Conversano E， Debiec H， Colucci M， et al.A child with semaphorin 3b-associated membranous nephropathy effectively treated with obinutuzumab after rituximab resistance［J］.Pediatr Nephrol， 2024， 39 (1): 305-308.
|
| 12 |
Goede V， Klein C， Stilgenbauer S.Obinutuzumab(GA101) for the treatment of chronic lymphocytic leukemia and other B-cell non-hodgkin's lymphomas: a glycoengineered type II CD20 antibody ［J］.Oncol Res Treat， 2015， 38 (4): 185-192.
|
| 13 |
Boyer-Suavet S， Andreani M， Lateb M， et al.Neutralizing anti-rituximab antibodies and relapse in membranous nephropathy treated with rituximab ［J］.Front Immunol， 2020 (10): 3069.
|
| 14 |
Mossner E， Brünker P， Moser S， et al.Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated Bcell cytotoxicity［J］.Blood， 2010， 115 (22): 4393-4402.
|
| 15 |
Edelmann J， Gribben JG.Obinutuzumab for the treatment of indolent lymphoma ［J］.Future Oncol，2016， 12 (15): 1769-1781.
|
| 16 |
Freeman CL， Sehn LH.A tale of two antibodies:obinutuzumab versus rituximab ［J］.Br J Haematol，2018， 182 (1): 29-45.
|
| 17 |
Klomjit N， Fervenza FC， Zand L.Successful treatment ofpatientswithrefractoryPLA2R-associated membranous nephropathy with obinutuzumab: a report of 3 cases［J］.Am J Kidney Dis， 2020， 76 (6): 883-888.
|
| 18 |
Hudson R， Rawlings C， Mon SY， et al.Treatment resistant M-type phospholipase A2 receptor associated membranous nephropathy responds to obinutuzumab: a report of two cases ［J］.BMC Nephrol， 2022， 23 (1):134.
|
| 19 |
Ginthor NE， Artinger K， Pollheimer MJ， et al. Membranous nephropathy associated with immunoglobulin G4-related disease successfully treated with obinutuzumab ［J］. Clin Kidney J， 2022， 15 (3): 564-566.
|
| 20 |
Naik S， Shukla S， Av N， et al.Obinutuzumab in refractoryphospholipaseA2receptor-associated membranous nephropathy with severe CKD ［J］.Kidney Int Rep， 2023， 8 (4): 942-943.
|
| 21 |
Teisseyre M， Boyer-Suavet S， Crémoni M， et al. Analysis and management of rituximab resistance in PLA2R1-associated membranous nephropathy ［J］. Kidney Int Rep， 2021， 6 (4): 1183-1188.
|
| 22 |
Deng L， Xu G.Update on the application of monoclonal antibody therapy in primary membranous nephropathy［J］.Drugs， 2023， 83 (6): 507-530.
|
| 23 |
Ragy O， Rautemaa V， Smith A， et al.Can use of the serum anti-PLA2R antibody negate the need for a renal biopsy in primary membranous nephropathy？［J］.PLoS One， 2023， 18 (2): e281726.
|
| 24 |
Cheng G， Liu J， Gilbert A， et al. Serum phospholipase A2 receptor antibodies and immunoglobulin G subtypes in adult idiopathic membranous nephropathy: clinical value assessment ［J］. Clin Chim Acta， 2019 (490): 135-141.
|
| 25 |
Bobart SA， Han H， Tehranian S， et al.Noninvasive diagnosisofPLA2R-associatedmembranous nephropathy: a validation study ［J］.Clin J Am Soc Nephrol， 2021， 16 (12): 1833-1839.
|
| 26 |
Katsumata Y， Okamoto Y， Moriyama T， et al.Clinical usefulness of anti-M-type phospholipase-A-receptor antibodies in patients with membranous nephropathy and the comparison of three quantification methods［J］.Immunol Med， 2020， 43 (1): 47-56.
|
| 27 |
Li W， Zhao Y， Fu P.Diagnostic test accuracy of serum anti-PLA2R autoantibodies and glomerular PLA2R antigen for diagnosing idiopathic membranous nephropathy: an updated meta-analysis ［J］.Front Med(Lausanne)， 2018 (5): 101.
|
| 28 |
van de Logt AE， Hofstra JM， Wetzels JF. Serum anti- PLA2R antibodies can be initially absent in idiopathic membranous nephropathy: seroconversion after prolonged follow-up ［J］. Kidney Int， 2015， 87 (6): 1263-1264.
|
| 29 |
莫小乔，胡喆莹，廖冬花，等.脓毒症继发急性肾损伤患者死亡风险预测模型构建及评估［J/CD］.中华危重症医学杂志（电子版），2023，16（3）：198-206.
|
| 30 |
闫美辰，庞明敏，刘光凤，等.脓毒症相关急性肾损伤诊断和评估指标的研究进展［J/CD］.中华危重症医学杂志（电子版），2023，16（5）：414-421.
|
| 31 |
Marcus R， Davies A， Ando K， et al.Obinutuzumab for the first-line treatment of follicular lymphoma［J］.N Engl J Med， 2017， 377 (14): 1331-1344.
|
| 32 |
Freeman CL， Morschhauser F， Sehn L， et al.Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusionrelated reactions ［J］.Blood， 2015， 126 (24): 2646-2649.
|